Managing AMD and GA Progression: Insights from the AREDS & AREDS2 10-Year Follow-Up

Post-Test

COPE Course ID: 101219-TD
Activity Event Number: # xxx
Credit hours: 1.0 hour

Question Title

1. Contact Information (To receive credits)

Name

Address

E-Mail

OE TRACKER#:

Question Title

2. Which supplement combination in the original AREDS trial showed a 25% reduction in the risk of progression to late AMD?

Antioxidants plus zinc

Zinc and copper only

Vitamin C and beta-carotene

Omega-3 fatty acidsular surface damage only

Question Title

3. Why was beta-carotene removed from the AREDS2 formulation?

It lacked efficacy in reducing AMD progression

It was shown to cause liver damage

It increased the risk of lung cancer in smokers

It interfered with absorption of lutein

Question Title

4. According to the AREDS2 10-year follow-up study, which formulation showed sustained benefits in reducing progression to late AMD?

Original AREDS with beta-carotene

Placebo

DHA alone

Lutein/Zeaxanthin in place of beta-carotene

Question Title

5. Which dietary pattern was associated with reduced risk of AMD progression and slower GA lesion growth?

High protein diet

Low-fat American Heart Association diet

Mediterranean diet

Vegetarian diet

Question Title

6. For which group of patients is the AREDS formulation not recommended?

Patients with bilateral intermediate AMD

Current smokers

Patients with advanced AMD in one eye

Patients over 65 with mild cataracts

Question Title

7. Which of the following components of the Mediterranean diet was most associated with reduced risk of progression to GA

Nuts

Fish

Red wine

Whole grains

Question Title

8. What was the primary goal of the AREDS2 clinical trial?

To determine the impact of diet on AMD progression

To evaluate the role of intraocular injections in dry AMD

To test the addition of lutein/zeaxanthin and omega-3s to the AREDS formula

To compare surgical vs. pharmaceutical treatments for AMD

Question Title

9. Which statement best reflects the effect of AREDS2 supplements on GA?

AREDS2 supplements reverse GA

AREDS2 supplements reduce GA incidence and slow its expansion

AREDS2 supplements are only effective for neovascular AMD

AREDS2 supplements had no measurable effect on GA

Question Title

10. Which ocular characteristic is associated with faster geographic atrophy expansion?

Central foveal involvement

Small, single GA lesions

Multifocal GA configuration

Absence of drusen

Question Title

11. What role does patient counseling play in AMD management according to the presentation?

It is essential for discussing supplements and diet adherence

It should focus only on genetic risk factors

It is secondary to pharmaceutical intervention

It should be limited to surgical options

Managing AMD and GA Progression: Insights from the AREDS & AREDS2 10-Year Follow-Up

Post-Test

Question Title

* 1. Contact Information (To receive credits)

Question Title

* 2. Which supplement combination in the original AREDS trial showed a 25% reduction in the risk of progression to late AMD?

Question Title

* 3. Why was beta-carotene removed from the AREDS2 formulation?

Question Title

* 4. According to the AREDS2 10-year follow-up study, which formulation showed sustained benefits in reducing progression to late AMD?

Question Title

* 5. Which dietary pattern was associated with reduced risk of AMD progression and slower GA lesion growth?

Question Title

* 6. For which group of patients is the AREDS formulation not recommended?

Question Title

* 7. Which of the following components of the Mediterranean diet was most associated with reduced risk of progression to GA

Question Title

* 8. What was the primary goal of the AREDS2 clinical trial?

Question Title

* 9. Which statement best reflects the effect of AREDS2 supplements on GA?

Question Title

* 10. Which ocular characteristic is associated with faster geographic atrophy expansion?

Question Title

* 11. What role does patient counseling play in AMD management according to the presentation?

1. Contact Information (To receive credits)

2. Which supplement combination in the original AREDS trial showed a 25% reduction in the risk of progression to late AMD?

3. Why was beta-carotene removed from the AREDS2 formulation?

4. According to the AREDS2 10-year follow-up study, which formulation showed sustained benefits in reducing progression to late AMD?

5. Which dietary pattern was associated with reduced risk of AMD progression and slower GA lesion growth?

6. For which group of patients is the AREDS formulation not recommended?

7. Which of the following components of the Mediterranean diet was most associated with reduced risk of progression to GA

8. What was the primary goal of the AREDS2 clinical trial?

9. Which statement best reflects the effect of AREDS2 supplements on GA?

10. Which ocular characteristic is associated with faster geographic atrophy expansion?

11. What role does patient counseling play in AMD management according to the presentation?